Lymphoproliferative skin lesion as a previously unreported adverse event detected in a patient receiving mSTR TB treatment. (2022). Journal of Pharmacovigilance and Drug Research, 3(2), 34-37. https://doi.org/10.53411/jpadr.2022.3.2.7